Sport, Ethics and Philosophy, Volume 5, Issue 2, Page 161-174, May 2011.

I argue that several recent criticisms Lopez Frias has made against my conventionalist version of broad internalism fail to hit their mark. I further argue that the author's use of Habermas's account of discourse ethics to make his criticisms also misfires because Habermas expressly warned against using his account to resolve normative conflicts that arise from the often conflicting ways different communities order their ethical lives, to include their athletic lives. My main aim in responding to Lopez Frias was to (...) bring critical attention to the normative difficulties that result when we cannot agree on how sport should be done because we cannot agree on what is/are the purpose of sport. (shrink)

Scholars such as Simon (2007; 2004) and Loland (2002) as well as the authors of the World Anti-Doping Code (2001) argue that using performance-enhancing substances is unhealthy and unfairly coercive for other athletes. Critics of the anti-doping position such as Hoberman (1995), Miah et al. (2005) and Tamburrini (2007) are quick to argue that such prohibitions, even though well-intended, constitute an unjustifiable form of paternalism. However, advocates for both of these positions assume that preserving good health and, conversely, avoiding health-related (...) harms, lie at the centre of the debate. Given the apparent stalemate in the debate over the validity of health concerns on performance-enhancing drugs, in this essay, I investigate ethical issues of ‘harm-free’ pharmaceutical performance enhancement. Beginning with the hypothesis that a harm-free performance-enhancing drug may be produced in the future, I ask if there would still be compelling reasons for prohibiting such a drug. I address this question by providing two arguments against allowing athletes to use pharmaceutical performance-enhancing drugs – the damage to the testing and contesting of sport and the loss of internal goods that are intrinsically satisfying. These two arguments taken together, I argue, are sufficient to sustain the prohibition of pharmaceutical performance-enhancing drugs without citing their harmful side effects. (shrink)